EQS-News: Boditech Med and SphingoTec close global licensing agreement for kidney function biomarker Proenkephalin A 119-159 (penKid)
Retrieved on:
Sunday, November 27, 2022
IVD, Hypertension, Hennigsdorf, Critical Care (journal), Gangwon, Acute kidney injury, Diagnosis, AKI, Partnership, Physician, Renal replacement therapy, Patient, South Korea, Degenerative disease, Biomarker, Critical care, Glomerular filtration rate, Septic shock, Inflammation, Spectrophotometry, Diabetes, Infection, Cancer, Korea, Hollinger, Jean-Louis Vincent, GFR, Kidney, Clinical Chemistry and Laboratory Medicine, Pharmaceutical industry, Medical imaging, Hospital, Sepsis
Gangwon-do, Republic of Korea and Hennigsdorf/Berlin, Germany, November 15, 2022 - Boditech Med Inc. (Boditech) and SphingoTec GmbH (SphingoTec) today announced they have entered into a non-exclusive royalty-bearing license agreement.
Key Points:
- Gangwon-do, Republic of Korea and Hennigsdorf/Berlin, Germany, November 15, 2022 - Boditech Med Inc. (Boditech) and SphingoTec GmbH (SphingoTec) today announced they have entered into a non-exclusive royalty-bearing license agreement.
- The critical state is currently diagnosed by standard-of-care biomarkers when 50% of the kidney function is already lost (1).
- PenKid addresses these pitfalls, offering an earlier and more precise determination of kidney function in acute and critical care settings (2).
- Proenkephalin A 119-159 (Penkid) Is an Early Biomarker of Septic Acute Kidney Injury: The Kidney in Sepsis and Septic Shock (Kid-SSS) Study.